Seeking scalable flow-through methods to separate monomers from aggregates
The use of proteins as drugs is an important, and growing, sector in the pharmaceutical market. Antibodies, proteins and peptides are used. They are expressed in mammalian cells, grown in large fermenters containing 1000L (or more) of culture media. The target protein is secreted into solution and must be purified.
Proteins can aggregate during production. The aggregated protein must be removed from solution. Aggregation reduces the biological activity of proteins and it is critically important that biopharmaceuticals are highly active.
We are seeking scalable flow-through methods to separate monomers from aggregates. We are looking at continuous media manufacturing and this technology will help provide additional sterility assurance. We are keen identify partners who can sell, supply or collaborate with us to develop appropriate technology.
• Yields of monomer > 70%
• Overall purity of product is maintained
• Works with proteins from approximately 25kDa to 160kDa
GSK is open to all approaches capable of achieving the criteria set forth above.
Bind and elute method.
We are looking for concise, non-confidential proposals. The proposal should:
• Describe the technical approach
• Include a description of the responding organisation or team and their experience
Please use the Respond button in order to submit your proposal.
• including a concise abstract summarising your submission
• attaching your proposal
• attaching any additional documents
Please note that only non-confidential information can be accepted. By submitting a response you confirm that the response does not contain any confidential information.